| abstract |
The present invention provides antibodies and methods for their preparation that have been altered to reduce the propensity to aggregate. The present invention also provides stable soluble scFv antibodies and Fab fragments specific for TNF comprising specific light and heavy chain sequences optimized specifically for the stability, solubility, in vitro and in vivo binding of TNF, and hypoimmunogenicity. Also disclosed are nucleic acids, vectors and host cells for expressing the recombinant antibodies of the present invention, methods for their isolation and use of the antibodies in medicine. |